A Decay-accelerating Factor-binding Strain of Coxsackievirus B3 Requires the Coxsackievirus-adenovirus Receptor Protein to Mediate Lytic Infection of Rhabdomyosarcoma Cells
Overview
Authors
Affiliations
The composition of the cellular receptor complex for coxsackievirus B3 (CVB3) has been an area of much contention for the last 30 years. Recently, two individual components of a putative CVB3 cellular receptor complex have been identified as (i) decay-accelerating factor (DAF) and (ii) the coxsackievirus-adenovirus receptor protein (CAR). The present study elucidates the individual roles of DAF and CAR in cell entry of CVB3 Nancy. First, we confirm that the DAF-binding phenotype of CVB3 correlates to the presence of key amino acids located in the viral capsid protein, VP2. Second, using antibody blockade, we show that complete protection of permissive cells from infection by high input multiplicities of CVB3 requires a combination of both anti-DAF and anti-CAR antibodies. Finally, it is shown that expression of the CAR protein on the surface of nonpermissive DAF-expressing RD cells renders them highly susceptible to CVB3-mediated lytic infection. Therefore, although the majority of CVB3 Nancy attaches to the cell via DAF, only virus directly interacting with the CAR protein mediates lytic infection. The role of DAF in CVB3 cell infection may be analogous to that recently described for coxsackievirus A21 (D. R. Shafren, D. J. Dorahy, R. A. Ingham, G. F. Burns, and R. D. Barry, J. Virol. 71:4736-4743, 1997), in that DAF may act as a CVB3 sequestration site, enhancing viral presentation to the functional CAR protein.
Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.
Dong W, Luo Y, He D, Zhang M, Zeng J, Chen Y Front Immunol. 2024; 15:1473288.
PMID: 39430750 PMC: 11486668. DOI: 10.3389/fimmu.2024.1473288.
Sakamoto A, Inoue H, Miyamoto S, Ito S, Soda Y, Tani K Sci Rep. 2023; 13(1):5924.
PMID: 37046036 PMC: 10097657. DOI: 10.1038/s41598-023-33126-x.
Vaccines against Group B Coxsackieviruses and Their Importance.
Mone K, Lasrado N, Sur M, Reddy J Vaccines (Basel). 2023; 11(2).
PMID: 36851152 PMC: 9961666. DOI: 10.3390/vaccines11020274.
Myocardial Damage by SARS-CoV-2: Emerging Mechanisms and Therapies.
Ho H, Peischard S, Strutz-Seebohm N, Klingel K, Seebohm G Viruses. 2021; 13(9).
PMID: 34578462 PMC: 8473126. DOI: 10.3390/v13091880.
Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M Cancers (Basel). 2021; 13(11).
PMID: 34199429 PMC: 8199618. DOI: 10.3390/cancers13112761.